My name is Matthew Mouawad. I am a third-year PhD student in the department of Medical Biophysics at Western University working under the supervision of Drs. Stewart Gaede and Neil Gelman.
With the high prevalence of breast cancers (1 in 9 women) in North America, we need to find ways to minimize the emotional and physical burden on patients and explore more efficient treatment techniques. Currently, breast-conserving therapies will often include five weeks of post-surgery radiotherapy, which can be prohibitively long for many patients. Furthermore, we currently do not have methods to non-invasively evaluate tumour control at an early stage.
To address these two limitations, London Regional Cancer Program is conducting a clinical trial headed by Drs. Muriel Brackstone, Michael Lock, and Brian Yaremko that is looking to reduce treatment time from five weeks to a single session, using high-dose radiotherapy. My role in this project is to use imaging we acquire from the hybrid PET-MRI at St. Joseph’s hospital to assess tumour control within seven days of treatment! The treatment technique would minimize patient burden significantly and the imaging would allow us to explore alternative ways to treat patients and potentially allow for adaptive patient treatment techniques.
We have successfully treated 14 patients using the new high-dose radiotherapy technique and have developed an imaging protocol that will allow us to investigate various tumour biomarkers. I look forward to presenting the most recent results in an manuscript within the next few months.
Thank you to BCSC for your trainee support!
- Matthew Mouawad, CAMPEP PhD candidate
Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit, London Health Sciences Centre